

**NEW
OS DATA**

In the treatment of resectable EGFRm NSCLC

Target the driver of disease with TAGRISSO

The only adjuvant targeted treatment to significantly extend DFS and now OS¹⁻³

Overall survival in resected stage IB-IIIa^{3†}

NEW

STATISTICALLY SIGNIFICANT OS

51%

reduced risk of death

vs placebo; HR=0.49 (95% CI: 0.34, 0.70); P<0.0001; N=682

- Median OS was not reached in either TAGRISSO or placebo arm

SAFETY SUMMARY

At the final analysis of disease-free survival data, when all patients had completed or discontinued the trial regimen, an updated safety analysis was published^{2,4}; the safety profile of osimertinib with extended follow-up^{2,4} was consistent with the results of the ADAURA primary analysis⁵

CI, confidence interval; DFS, disease-free survival; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival.

References: 1. Tagrisso (osimertinib) Singapore Prescribing information. 2. Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIA non-small-cell lung cancer: updated results from the phase II randomized ADAURA trial [published online ahead of print January 31, 2023]. *J Clin Oncol*. doi:10.1200/JCO.2022.02186. 3. Herbst RS, Tsuijoi M, John T, et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIA non-small cell lung cancer (NSCLC). Presented at: 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. 4. John T, Grohé C, Goldman JW, et al. Three-year safety, tolerability, and health-related quality of life outcomes of adjuvant osimertinib in patients with resected stage IB-IIA EGFR-mutated non-small cell lung cancer: updated analysis from the phase 3 ADAURA trial. *J Thorac Oncol* 2023 (in press). 5. Wu Y-L, Tsuijoi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. *N Engl J Med* 2020;383:1711-1723.

For Healthcare Professionals Only



Scan the QR code to access the full Tagrisso Prescribing Information.

AstraZeneca

AstraZeneca Singapore Pte Ltd
10 Kallang Avenue # 12-10, Aperia Tower 2, Singapore 339510
Tel: +65 6812 4700 Fax: +65 6385 3050

TAGRISO is a registered trademark of the AstraZeneca group of companies. ©2023 AstraZeneca. All rights reserved.
SG-8553 Date of Approval: 28/08/2023

TAGRISO[®]
osimertinib